EFFECT OF TRANSCUTANEOUS VERSUS PERCUTANEOUS TIBIAL NERVE STIMULATION ON OVER ACTIVE BLADDER IN POST MENOPAUSAL WOME
Not Applicable
- Conditions
- Urological and Genital Diseases
- Registration Number
- PACTR201911868991836
- Lead Sponsor
- Faculty of Physical Therapy Cairo University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Female
- Target Recruitment
- 70
Inclusion Criteria
•Post-menopausal women suffering from pure urge urinary incontinence.
•Their age will range from 55-65 years old.
•Their body mass index (BMI) will range from 25-29.9 kg/m2.
•They will experience menopause at least for 3 years.
Exclusion Criteria
Post-menopausal women will be excluded if they had:
•Urinary tract infection
•Previous surgery for urinary incontinence
•Upper motor neuron diseases
•History of genito-urinary cancer
•Previous pelvic irradiation
•Pure stress urinary incontinence
•Genital prolapse
•Diabetes mellitus
•Pace maker
•Metal implantation.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 3-Day Bladder diary. It will be used to record the number of voids and number of incontinent episodes per day for each woman in all groups ;Pad test. It will be used to confirm and quantify the urine leakage for each woman in all groups (A,B&C). It is a simple noninvasive inexpensive, and easy method to evaluate the effect of treatment modalities for incontinence. Long duration (24 to 48 hours) pad test will be used ;Urodynamic Investigation System. It will also be used to measure the volume at first desire to void, first sensation of bladder filling (1st SBF) during cystometry, and maximum bladder capacity (MBC).
- Secondary Outcome Measures
Name Time Method Overactive Bladder questionnaire Short Form (OAB-q SF): It will be used to assess symptoms and health-related quality of life (HR-QOL) for each woman in all groups (A,B&C). It is a brief, self-administered patient-reported outcomes tool with two scales. It is internally consistent, valid, and responsive to treatment-related change.